Stocks and Investing
Stocks and Investing
Mon, August 14, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Salim Syed Maintained (BBIO) at Strong Buy with Increased Target to $60 on, Aug 14th, 2023
Salim Syed of Mizuho, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $50 to $60 on, Aug 14th, 2023.
Salim has made no other calls on BBIO in the last 4 months.
There are 4 other peers that have a rating on BBIO. Out of the 4 peers that are also analyzing BBIO, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $33 on, Tuesday, July 18th, 2023
These are the ratings of the 3 analyists that currently disagree with Salim
- Dane Leone of "Raymond James" Maintained at Buy with Increased Target to $46 on, Tuesday, July 18th, 2023
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $50 on, Tuesday, July 18th, 2023
- Josh Schimmer of "Evercore ISI Group" Initiated at Buy and Held Target at $40 on, Wednesday, April 19th, 2023
Contributing Sources